Drugs With Anticholinergic Properties, Cognitive Decline, and Dementia in an Elderly General Population
- 27 July 2009
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Internal Medicine
- Vol. 169 (14), 1317-24
- https://doi.org/10.1001/archinternmed.2009.229
Abstract
Despite the high intake of medications with anticholinergic properties by community-dwelling elderly persons, the effects on cognitive decline and dementia have rarely been evaluated. Participants were 4128 women and 2784 men 65 years or older from a population-based cohort recruited from 3 French cities. Cognitive performance, clinical diagnosis of dementia, and anticholinergic use were evaluated at baseline and 2 and 4 years later. A total of 7.5% of the participants reported anticholinergic drug use at baseline. Multivariate-adjusted logistic regression indicated that women reporting use of anticholinergic drugs at baseline showed greater decline over 4 years in verbal fluency scores (odds ratio [OR], 1.41; 95% confidence interval [CI], 1.11-1.79) and in global cognitive functioning (OR, 1.22; 95% CI, 0.96-1.55) than women not using anticholinergic drugs. In men, an association was found with decline in visual memory (OR, 1.63; 95% CI, 1.08-2.47) and to a lesser extent in executive function (OR, 1.47; 95% CI, 0.89-2.44). Notable interactions were observed in women between anticholinergic use and age, apolipoprotein E, or hormone therapy. A 1.4- to 2-fold higher risk of cognitive decline was observed for those who continuously used anticholinergic drugs but not for those who had discontinued use. The risk of incident dementia over the 4-year follow-up period was also increased in continuous users (hazard ratio [HR], 1.65; 95% CI, 1.00-2.73) but not in those who discontinued the use of anticholinergic drugs (HR, 1.28; 95% CI, 0.59-2.76). Elderly people taking anticholinergic drugs were at increased risk for cognitive decline and dementia. Discontinuing anticholinergic treatment was associated with a decreased risk. Physicians should carefully consider prescription of anticholinergic drugs in elderly people, especially in the very elderly and in persons at high genetic risk for cognitive disorder.Keywords
This publication has 39 references indexed in Scilit:
- Drugs With Anticholinergic Properties as a Risk Factor for Cognitive Impairment in Elderly PeopleJournal of Clinical Psychopharmacology, 2008
- Vascular Factors and Risk of Dementia: Design of the Three-City Study and Baseline Characteristics of the Study PopulationNeuroepidemiology, 2003
- Increased Anticholinergic Challenge-Induced Memory Impairment Associated with the APOE-ɛ4 Allele in the Elderly: A Controlled Pilot StudyNeuropsychopharmacology, 2003
- Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugsAnnals of Neurology, 2003
- Chronic Exposure to Anticholinergic Medications Adversely Affects the Course of Alzheimer DiseaseAmerican Journal of Geriatric Psychiatry, 2003
- Serum Anticholinergic Activity in a Community-Based Sample of Older AdultsArchives of General Psychiatry, 2003
- M1 Muscarinic Agonists Can Modulate Some of the Hallmarks in Alzheimer's Disease: Implications in Future TherapyJournal of Molecular Neuroscience, 2003
- Potentially reversible conditions in 1000 consecutive memory clinic patientsJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Classification criteria for mild cognitive impairmentNeurology, 2001
- Estrogen use, APOE, and cognitive declineNeurology, 2000